Pharma Reaserch Prod Co Ltd (214450) - Net Assets
Based on the latest financial reports, Pharma Reaserch Prod Co Ltd (214450) has net assets worth ₩723.88 Billion KRW (≈ $490.56 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.04 Trillion ≈ $707.43 Million USD) and total liabilities (₩320.01 Billion ≈ $216.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore total assets of Pharma Reaserch Prod Co Ltd for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩723.88 Billion |
| % of Total Assets | 69.34% |
| Annual Growth Rate | 16.53% |
| 5-Year Change | 136.99% |
| 10-Year Change | 321.74% |
| Growth Volatility | 9.56 |
Pharma Reaserch Prod Co Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Pharma Reaserch Prod Co Ltd's net assets have evolved over time, based on quarterly financial data. Check how tangible is Pharma Reaserch Prod Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Pharma Reaserch Prod Co Ltd (2015–2025)
The table below shows the annual net assets of Pharma Reaserch Prod Co Ltd from 2015 to 2025. For live valuation and market cap data, see how much is Pharma Reaserch Prod Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩723.88 Billion ≈ $490.56 Million |
+27.12% |
| 2024-12-31 | ₩569.44 Billion ≈ $385.90 Million |
+23.20% |
| 2023-12-31 | ₩462.19 Billion ≈ $313.22 Million |
+34.55% |
| 2022-12-31 | ₩343.50 Billion ≈ $232.79 Million |
+12.46% |
| 2021-12-31 | ₩305.44 Billion ≈ $206.99 Million |
+24.46% |
| 2020-12-31 | ₩245.42 Billion ≈ $166.32 Million |
+17.39% |
| 2019-12-31 | ₩209.07 Billion ≈ $141.69 Million |
+5.79% |
| 2018-12-31 | ₩197.62 Billion ≈ $133.93 Million |
+10.50% |
| 2017-12-31 | ₩178.85 Billion ≈ $121.21 Million |
+4.20% |
| 2016-12-31 | ₩171.64 Billion ≈ $116.32 Million |
+9.50% |
| 2015-12-31 | ₩156.75 Billion ≈ $106.23 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pharma Reaserch Prod Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1312.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩492.07 Billion | 71.38% |
| Other Components | ₩197.26 Billion | 28.62% |
| Total Equity | ₩689.33 Billion | 100.00% |
Pharma Reaserch Prod Co Ltd Competitors by Market Cap
The table below lists competitors of Pharma Reaserch Prod Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
$2.38 Billion |
|
AstraZeneca PLC
LSE:AZN
|
$2.38 Billion |
|
Nektar Therapeutics
NASDAQ:NKTR
|
$2.38 Billion |
|
Pfizer Limited
NSE:PFIZER
|
$2.39 Billion |
|
eToro Group Ltd.
NASDAQ:ETOR
|
$2.38 Billion |
|
Yantai Eddie Precision Mach
SHG:603638
|
$2.38 Billion |
|
BRP Inc.
NASDAQ:DOO
|
$2.38 Billion |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
$2.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharma Reaserch Prod Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 539,402,310,120 to 689,331,204,110, a change of 149,928,893,990 (27.8%).
- Net income of 165,120,956,450 contributed positively to equity growth.
- Dividend payments of 11,728,612,800 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩165.12 Billion | +23.95% |
| Dividends Paid | ₩11.73 Billion | -1.7% |
| Other Changes | ₩-3.46 Billion | -0.5% |
| Total Change | ₩- | 27.80% |
Book Value vs Market Value Analysis
This analysis compares Pharma Reaserch Prod Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.54x to 5.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩18256.70 | ₩338500.00 | x |
| 2017-12-31 | ₩19149.48 | ₩338500.00 | x |
| 2018-12-31 | ₩20891.66 | ₩338500.00 | x |
| 2019-12-31 | ₩22197.68 | ₩338500.00 | x |
| 2020-12-31 | ₩25424.35 | ₩338500.00 | x |
| 2021-12-31 | ₩30617.97 | ₩338500.00 | x |
| 2022-12-31 | ₩34433.26 | ₩338500.00 | x |
| 2023-12-31 | ₩42492.31 | ₩338500.00 | x |
| 2024-12-31 | ₩52145.39 | ₩338500.00 | x |
| 2025-12-31 | ₩66347.89 | ₩338500.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharma Reaserch Prod Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.79%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.51x
- Recent ROE (23.95%) is above the historical average (12.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 8.22% | 34.38% | 0.22x | 1.08x | ₩-2.80 Billion |
| 2016 | 8.10% | 30.27% | 0.26x | 1.04x | ₩-3.26 Billion |
| 2017 | 7.24% | 23.78% | 0.29x | 1.06x | ₩-4.93 Billion |
| 2018 | 7.29% | 22.41% | 0.25x | 1.31x | ₩-5.35 Billion |
| 2019 | 7.97% | 19.87% | 0.31x | 1.29x | ₩-4.24 Billion |
| 2020 | 13.35% | 30.14% | 0.34x | 1.30x | ₩8.23 Billion |
| 2021 | 15.29% | 30.30% | 0.36x | 1.40x | ₩16.14 Billion |
| 2022 | 11.81% | 20.83% | 0.41x | 1.39x | ₩6.23 Billion |
| 2023 | 17.68% | 29.33% | 0.49x | 1.24x | ₩33.24 Billion |
| 2024 | 17.06% | 26.29% | 0.41x | 1.59x | ₩38.10 Billion |
| 2025 | 23.95% | 30.79% | 0.51x | 1.51x | ₩96.19 Billion |
Industry Comparison
This section compares Pharma Reaserch Prod Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $202,051,042,045
- Average return on equity (ROE) among peers: -14.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharma Reaserch Prod Co Ltd (214450) | ₩723.88 Billion | 8.22% | 0.44x | $2.38 Billion |
| ORIENTBIO Inc. (002630) | $44.21 Billion | 0.00% | 0.54x | $71.52 Million |
| Green Cross (005250) | $210.22 Billion | 1.73% | 6.63x | $283.20 Million |
| Green Cross Holdings Preference Shares (005257) | $1.38 Trillion | 3.43% | 0.63x | $2.29 Million |
| Pharmicell (005690) | $63.87 Billion | 14.80% | 0.48x | $411.92 Million |
| GeneOne Life Science Inc (011000) | $40.90 Billion | -126.78% | 1.91x | $164.07 Million |
| HLB Co. Ltd (028300) | $174.68 Billion | 14.51% | 0.74x | $2.76 Billion |
| Mgenplus Co. Ltd. (032790) | $10.14 Billion | -54.19% | 2.17x | $16.13 Million |
| Daesung Microbiological Labs. Co. Ltd (036480) | $35.42 Billion | 1.69% | 0.64x | $15.71 Million |
| Seoulin Bioscience Co.Ltd (038070) | $41.57 Billion | 10.01% | 0.45x | $24.62 Million |
| Hyundai Bioscience Co. Ltd (048410) | $22.49 Billion | -13.82% | 0.46x | $384.00 Million |
About Pharma Reaserch Prod Co Ltd
PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly… Read more